on twittergrants & donationsphoto galleryvideo galleryemployee videosscience and research videostransparence des lienspersonnes physiquespersonnes moralesiclusig overviewabout iclusigariad pass healthcare professionalspatients & caregiversresearch & developmentoverviewpipelineour scienceponatinibcml and ph allamlgistexpanded access programother targetsbrigatinibclinical trialspotential against alkap32788clinical trialspublicationsinvestigator sponsored trialsinvestorsoverviewnews releasesevents & presentationspresentationsinvestor downloadsstock informationstock quote & charthistorical lookupcost basis calculatorownership summaryanalyst coveragefinancial informationfundamentalsquarterly resultsearnings estimatessec filingsinvestor kitproxy materialscorporate governanceemail alertsir contactscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery discovering a disciplined highly targeted approach to discovering new cancer medicines go developing rigorous definitive clinical trials based on deep oncology expertise go delivering committed to bringing differentiated new cancer medicines to patients go iclusig ponatinib ariad s first internally discovered and developed medicine go discovering a disciplined highly targeted approach to discovering new cancer medicines developing rigorous definitive clinical trials based on deep oncology expertise delivering committed to bringing differentiated new cancer medicines to patients iclusig ponatinib ariad s first internally discovered and developed medicine brigatinib up next in our pipeline an fda breakthrough therapy under investigation in alk nsclc learn more a remarkable place doing remarkable work we re looking for people who want to make a difference for cancer patients open positions a unique highly targeted approach to cancer our research & development program learn more news & features latest news 10 10 16 ariad presents updated long term follow up results from the phase 1 2 trial on investigational drug brigatinib at 2016 esmo meeting read more 9 28 16 ariad announces regulatory approval for iclusig ponatinib in japan read more twitter feed ariadpharmaceuticals ariadpharmwe re proud to support nsclc & lungcancer patients today with free2breathe lungcancerphilly penncancer1 day agoariadpharmaceuticals ariadpharmfor patients with alk nsclc tumors may develop resistance . dr. jahanzeb discusses the challenges of progression https t.co u3pud4qbx83 days ago print page share page our photo gallery follow us about ariadoverviewcontact infoour name & logoour destinationour vision & cultural dnacompany leadershipboard of directorspressroomgrants & donationsphoto galleryvideo gallerytransparence des liensiclusig overviewabout iclusigariad pass healthcare professionalspatients & caregiversresearch & developmentoverviewpipelineour scienceponatinibbrigatinibap32788clinical trialspublicationsinvestigator sponsored trialsinvestorsoverviewnews releasesevents & presentationsinvestor downloadsstock informationfinancial informationsec filingsinvestor kitproxy materialscorporate governanceemail alertsir contactscareersoverviewour visionemployee benefitscurrent opportunitieseeoephoto gallery product information provided on this site is intended only for u.s. residents . 2016 ariad pharmaceuticals inc. all rights reserved . terms and conditions privacy policy forward looking statement map & directions